Roche has filed an IND with the FDA for a Genmab antibody developed under the companies’ collaboration. Genmab will receive a milestone payment from Roche. Under the agreement with Roche, Genmab uses its antibody expertise and development capabilities to create human antibodies to a range of disease targets identified by Roche. Genmab receives milestone and royalty payments based on successful products. Genmab may also obtain rights to develop products based on disease targets identif...